{"id":"NCT02872103","sponsor":"EVIVE Biotechnology","briefTitle":"Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","officialTitle":"A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08","primaryCompletion":"2017-12-20","completion":"2017-12-20","firstPosted":"2016-08-19","resultsPosted":"2019-03-26","lastUpdate":"2021-05-05"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer","Neutropenia"],"interventions":[{"type":"DRUG","name":"F-627","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"F-627","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind and placebo controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with stage II-IV breast cancer receiving chemotherapy treatment.","primaryOutcome":{"measure":"The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo","timeFrame":"The first of 4, 21 Day Chemotherapy Cycles, an average of 3 weeks","effectByArm":[{"arm":"F-627","deltaMin":1.3,"sd":1.17},{"arm":"Placebo","deltaMin":3.9,"sd":1.35}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["38103088"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":83},"commonTop":["Nausea","Fatigue","Diarrhea","Stomatitis","Bone pain"]}}